News
Immodulon presents at International Society for Advancement of Cytometry CYTO Virtual 2020 conference on biomarker considerations in immunomodulator clinical trials
Presentation on different technologies to assess the impact of IMM-101 on the immune system in the approved phase 3 clinical trial for COVID-19 in cancer patients Uxbridge, UK – 4th August 2020 – Immodulon, the Immuno-oncology company, today announces that a...
Expansion of collaboration with Erasmus Medical Centre in metastatic pancreatic cancer
Additional investigator-initiated phase I/II study planned to investigate the safety and efficacy of IMM101 in limited metastatic pancreatic cancer; study could start by the end of 2020 Uxbridge, UK – 27 July 2020 – Immodulon, the immuno-oncology company, is pleased...
Immodulon announce FDA approval of an IND for a phase I/II study of IMM-101 in advanced sarcoma
The phase I/II trial will recruit up to 42 participants with inoperable leiomyosarcoma or dedifferentiated liposarcoma Uxbridge, UK – 28 May 2020 – Immodulon, the immuno-oncology company, today announces that the Company has received confirmation from the US Food and...
Immodulon announces appointment of Dr. Cellia Habita as Chief Medical Officer
Dr. Habita brings deep expertise in clinical drug development, as the Company continues to seek to progress its uniquely differentiated clinical programmes in immuno-oncology Uxbridge, UK – 14 April 2020 – Immodulon, the immuno-oncology company, announces the...
Immodulon announces Notice of Allowance for two U.S. Patent Applications related to IMM-101…
Immodulon announces Notice of Allowance for two U.S. Patent Applications related to IMM-101 in combination with Immune Checkpoint Inhibitors Claims cover methods of treating pancreatic cancer or melanoma with IMM-101 in combination with anti-PD-L1, anti-PD1 or...
Immodulon presents long-term survival data of IMM-101 in patients with advanced melanoma at The Society for Melanoma Research 2019 Congress
Positive results from phase 1 follow up study supports current phase 2 clinical trial of IMM-101 in combination with checkpoint inhibitor therapy Immodulon, the immuno-oncology company, today announces that long-term survival data from its phase 1 study in 18 patients...
Investigator-initiated phase I/II LAPC-2 study of IMM-101 in locally advanced pancreatic cancer
Phase 1/2 study to investigate safety and efficacy of IMM-101 in locally advanced pancreatic cancer Uxbridge, UK, 13 September 2019 – Immodulon, the immuno-oncology company, today announces that the Department of Surgery at the Erasmus Medical Center in Rotterdam is...
Immodulon appoints Professor Bams Abila as Chief Medical Officer
Professor Abila brings extensive experience in clinical drug development. Immodulon, the immuno-oncology company, announces the appointment of Professor Bams Abila, MD, PhD, FFPM, as Chief Medical Officer (CMO) of the Company with immediate effect. Professor Abila has...
Biodesix and Immodulon Announce Research Collaboration for Pancreatic Cancer Treatment
Biomarker Research for IMM-101 Utilizing the Biodesix Diagnostic Cortex™ Platform BOULDER, Colo. and UXBRIDGE, UK, July 25, 2019 – Biodesix Inc. and Immodulon Therapeutics Limited, the immune-oncology company, today announced that they have entered into a...
myTomorrows and Immodulon to develop Expanded Access Programme
Amsterdam, The Netherlands and Uxbridge, UK, 27 June, 2019 – myTomorrows, a Netherlands-based HealthTech company facilitating access to medicines in development and real-world data collection, and Immodulon, an immuno-oncology company, today announced a collaboration...